Leica Biosystems has announced the completion of its previously-announced takeover of breast biopsy specialist Devicor Medical Products.
The acquired business will now operate as a standalone unit within Leica Biosystems, with current chief executive officer Tom Daulton continuing to lead the organisation. No other financial terms and conditions have been disclosed.
“Leica Biosystems has completed its takeover of Devicor Medical Products, a leading producer of breast biopsy instruments and consumables.“
A global market leader in breast biopsy instruments and consumables, the company is responsible for products such as the Mammotome Breast Biopsy System, which has enabled more than four million women to have a minimally invasive breast biopsy.
It generates annual revenues of approximately $170 million (108.17 million pounds) and will help to broaden Leica's capabilities in this field.
Dr Matthias Weber, president of Leica Biosystems, said: "This acquisition supports our mission of advancing cancer diagnostics to improve lives by adding products that will have direct benefits for the patients and the clinicians who care for them."
Devicor is headquartered in Cincinnati, Ohio and has more than 550 employees, selling products in more than 50 countries around the world.See all the latest jobs in Science